Patents by Inventor Minglang Wu

Minglang Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted spirocyclic piperidine derivatives as histamine-3 (H3) receptor ligands
    Patent number: 8513232
    Abstract: The present invention provides compounds of Formula (I): their use as H3 antagonists/inverse agonists, processes for their preparation, and pharmaceuticals compositions thereof.
    Type: Grant
    Filed: July 29, 2010
    Date of Patent: August 20, 2013
    Assignees: Cephalon, Inc., Pharmacopeia, LLC
    Inventors: Edward R. Bacon, Nadine C. Becknell, Reddeppa reddy Dandu, Lisa Guise-Zawacki, Tao Guo, Chia-yu Huang, Robert L. Hudkins, Babu G. Sundar, Ming Tao, Minglang Wu, Allison L. Zulli
  • 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands
    Publication number: 20110213029
    Abstract: There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
    Type: Application
    Filed: May 6, 2011
    Publication date: September 1, 2011
    Applicants: Schering Corporation, Pharmacopeia Drug Discovery
    Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jianhua Chao, Younong Yu, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Purakkattle J. Biju, Kingsley H. Nelson, JR., Laura L. Rokosz, Gaifa Lai, James P. Jakway, Minglang Wu, Evan A. Hecker, Daniel Lundell, Jay S. Fine
  • Substituted Spirocyclic Piperidine Derivatives as Histamine-3 (H3) Receptor Ligands
    Publication number: 20110071131
    Abstract: The present invention provides compounds of Formula (I): their use as H3 antagonists/inverse agonists, processes for their preparation, and pharmaceuticals compositions thereof.
    Type: Application
    Filed: July 29, 2010
    Publication date: March 24, 2011
    Applicants: CEPHALON, INC., PHARMACOPEIA, INC.
    Inventors: Edward R. Bacon, Nadine C. Becknell, Reddeppa reddy Dandu, Lisa Guise-Zawacki, Tao Guo, Chia-yu Huang, Robert L. Hudkins, Babu G. Sundar, Ming Tao, Minglang Wu, Allison L. Zulli
  • Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands
    Patent number: 7691856
    Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula IA.
    Type: Grant
    Filed: January 9, 2007
    Date of Patent: April 6, 2010
    Assignees: Schering Corporation, Pharmacopeia, Inc.
    Inventors: Arthur G. Taveras, Jianhua Chao, Purakkattle J. Biju, Younong Yu, Cynthia J. Aki, J. Robert Merritt, Ge Li, John J. Baldwin, Gaifa Lai, Minglang Wu, Evan A. Hecker
  • Isothiazole dioxides as CXC- and CC-chemokine receptor ligands
    Patent number: 7671212
    Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.
    Type: Grant
    Filed: December 20, 2004
    Date of Patent: March 2, 2010
    Assignee: Schering Corporation
    Inventors: Arthur G. Taveras, J. Robert Merritt, John J. Baldwin, Junying Zheng, Purakkattle J. Biju, Younong Yu, Jianhua Chao, Gaifa Lai, Minglang Wu
  • 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS
    Publication number: 20090306079
    Abstract: There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
    Type: Application
    Filed: January 13, 2009
    Publication date: December 10, 2009
    Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jianhua Chao, Younong Yu, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Purakkattle J. Biju, Kingsley H. Nelson, JR., Laura L. Rokosz, Gaifa Lai, James P. Jakway, Minglang Wu, Evan A. Hecker, Daniel Lundell, Jay S. Fine
  • Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC-chemokine receptor ligands
    Publication number: 20070264230
    Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula IA.
    Type: Application
    Filed: January 9, 2007
    Publication date: November 15, 2007
    Inventors: Arthur Taveras, Jianhua Chao, Purakkattle Biju, Younong Yu, Jay Fine, William Hipkin, Cynthia Aki, J. Merritt, Ge Li, John Baldwin, Gaifa Lai, Minglang Wu, Evan Hecker
  • 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
    Publication number: 20070021494
    Abstract: There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
    Type: Application
    Filed: August 8, 2006
    Publication date: January 25, 2007
    Inventors: Arthur Taveras, Cynthia Aki, Richard Bond, Jianping Chao, Michael Dwyer, Johan Ferreira, Jianhua Chao, Younong Yu, John Baldwin, Bernd Kaiser, Ge Li, J. Merritt, Purakkattle Biju, Kingsley Nelson, Laura Rokosz, Gaifa Lai, James Jakway, Minglang Wu, Evan Hecker, Daniel Lundell, Jay Fine
  • 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
    Patent number: 7132445
    Abstract: There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
    Type: Grant
    Filed: July 30, 2003
    Date of Patent: November 7, 2006
    Assignees: Schering Corporation, Pharmacopeia Drug Discovery, Inc.
    Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jianhua Chao, Younong Yu, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Purakkattle J. Biju, Kingsley H. Nelson, Jr., Laura L. Rokosz, James P. Jakway, Gaifa Lai, Minglang Wu, Evan A. Hecker, Daniel Lundell, Jay S. Fine
  • Isothiazole dioxides as CXC- and CC-chemokine receptor ligands
    Publication number: 20060025453
    Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.
    Type: Application
    Filed: December 20, 2004
    Publication date: February 2, 2006
    Inventors: Arthur Taveras, J. Merritt, John Baldwin, Junying Zheng, Purakkattle Biju, Younong Yu, Jianhua Chao, Jay Fine, Daniel Lundell, Tony Priestley, Angelo Reggiani, Gaifa Lai, Minglang Wu
  • Thiadiazoledioxides and thiadiazoleoxides as CXC- and CC- chemokine receptor ligands
    Publication number: 20040186142
    Abstract: Disclosed are novel compounds of the formula: 1
    Type: Application
    Filed: October 7, 2003
    Publication date: September 23, 2004
    Applicant: Schering Corporation Pharmacopeia, Inc.
    Inventors: Arthur G. Taveras, Jianhua Chao, Purakkattle J. Biju, Younong Yu, Jay S. Fine, William Hipkin, Cynthia J. Aki, J. Robert Merritt, Ge Li, John J. Baldwin, Gaifa Lai, Minglang Wu, Evan A. Hecker
  • 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
    Publication number: 20040147559
    Abstract: There are disclosed compounds of the formula 1
    Type: Application
    Filed: July 30, 2003
    Publication date: July 29, 2004
    Applicant: Schering Corporation and Pharmacopeia, Inc.
    Inventors: Arthur G. Taveras, Cynthia J. Aki, Richard W. Bond, Jianping Chao, Michael Dwyer, Johan A. Ferreira, Jianhua Chao, Younong Yu, John J. Baldwin, Bernd Kaiser, Ge Li, J. Robert Merritt, Purakkattle J. Biju, Kingsley H. Nelson, Laura L. Rokosz, James P. Jakway, Gaifa Lai, Minglang Wu, Evan A. Hecker, Daniel Lundell, Jay S. Fine